← All organizations
Highest phase reached
Phase 4
First clinical trial
Jan 1, 1999First marketed drug
Jun 9, 1999First NDA
Dec 7, 2001Last known activity
Jul 20, 2021
Acquired by Sanofi-Aventis on Jan 1, 2004
Timeline
2000s
- Feb 25, 2000
fexofenadine— NDA Secondary Org
- Jul 12, 2002
rasburicase— Marketing Organization
- Aug 9, 2002
oxaliplatin— NDA Organization
- Jan 1, 2004
Sanofi-Aventis— Acquired By
- Jan 1, 2004
Aventis— Acquired
Drugs by trial phase (669 distinct, 2515 trials)
Phase 4 (1 own, 181 via acquisition)
Phase 3 (2 own, 208 via acquisition)
Phase 2 (0 own, 179 via acquisition)
Phase 1 (0 own, 71 via acquisition)
Other trials (0 own, 27 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Adenoma
- Alcohol Drinking
- Aortic Valve Stenosis
- Biliary Tract Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Cholangiocarcinoma
- Colorectal Neoplasms
- Constriction, Pathologic
- Coronary Artery Disease
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Digestive System Diseases
- Esophageal Neoplasms
- Fallopian Tube Neoplasms
- Gallbladder Neoplasms
- Gastrointestinal Diseases
- Gastrointestinal Neoplasms
- Heart Failure
- Hyperplasia
- Lung Neoplasms
- Lupus Erythematosus, Systemic
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Malaria
- Malaria, Cerebral
- Mental Disorders
- Neoplasm Metastasis
- Neoplasms, Unknown Primary
- Neuralgia
- Pancreatic Neoplasms
- Parasomnias
- Prodromal Symptoms
- Prostatic Hyperplasia
- Prostatic Neoplasms
- Psychotic Disorders
- Recurrence
- Salivary Gland Neoplasms
- Schizophrenia
- Sleep Initiation and Maintenance Disorders
- Sleep Wake Disorders
- Small Cell Lung Carcinoma
- Stomach Neoplasms
- Thrombosis
- Urinary Bladder Neoplasms
Marketed drugs (7)
Subsidiaries (3 direct, 45 total across the full acquisition tree)
- Aventis
- L'Oreal
- Sanofi
- Chinoin L2
- Clin Midy L2
- Hoechst Marion Roussel L2
- Kodak L2
- Rhone-Poulenc Rorer L2
- Synthelabo L2
- Applied Immunesciences L3
- Clin Comar L3
- Fisons L3
- Hoechst L3
- Laboratoires Dausse L3
- Laboratoires Delalande L3
- Laboratoires Midy L3
- Laboratoires Robert & Carriere L3
- Marion Merrell Dow L3
- Rhone Poulenc L3
- Rorer L3
- Sterling-Winthrop L3
- Byla Laboratories L4
- Comar & Co. L4
- Connaught Laboratories L4
- Frederick Stearns & Co. L4
- Laboratoires Clin L4
- Lloyd Brothers Pharmacists Inc L4
- Marion Laboratories L4
- Merrell Dow L4
- Pasteur Merieux L4
- Poulenc Freres L4
- Revlon L4
- Roussel-Uclaf L4
- Society of Rhone Chemical Factories L4
- Sterling Drug L4
- Theraplix L4
- Winthrop Chemical L4
- George A. Breon & Co. L5
- Greyhound Corp L5
- Hed Pharmaceuticals L5
- Laboratorios Grossman SA L5
- Merieux Institute L5
- Nysco Laboratories L5
- Sterling Remedy Company L5
- US Vitamin and Pharmaceutical Corporation L5
Recent trials (46)
- NCT04975152CollaboratorPhase 1Jul 20, 2021
- NCT02522572CollaboratorPhase 1/Phase 2Aug 1, 2015
- NCT02049203CollaboratorPhase 1Jan 1, 2014
- NCT01504620CollaboratorPhase 4Jan 1, 2011
- NCT01284959CollaboratorPhase 4Jun 1, 2010
- NCT00977938CollaboratorPhase 4Oct 1, 2009
- NCT00413361CollaboratorPhase 4Jun 1, 2007
- NCT00418093CollaboratorPhase 2Sep 1, 2006
- NCT00317915CollaboratorPhase 3Apr 24, 2006
- NCT00343876CollaboratorPhase 4Jul 1, 2005
- NCT00240097CollaboratorPhase 2Jun 1, 2005
- NCT00190307CollaboratorPhase 4Jun 1, 2005
- NCT00156533CollaboratorPhase 4Mar 1, 2005
- NCT00145418CollaboratorPhase 2Feb 1, 2005
- NCT00316433CollaboratorPhase 2Feb 1, 2005
Details
- Founded
- Paris, FR Jan 1, 1999
- First NDA
- Dec 7, 2001
- Last known activity
- Jul 20, 2021
Designations held
- Orphan drug
- Fast track
- Priority review
- Accelerated approval